摘要
目的分析达比加群酯抗凝治疗对非瓣膜性心房颤动(NVAF)患者血管功能的影响。方法回顾性分析2013年6月至2018年6月收治的120例NAVF患者的临床资料,根据治疗方法不同分为对照组(利伐沙班辅助治疗)和观察组(达比加群酯辅助治疗),分析两组患者治疗后的临床疗效。结果治疗12周后,观察组患者总有效率为93.33%,对照组为76.67%,观察组患者总有效率高于对照组(P<0.05)。治疗前后两组患者肝功能比较差异无统计学意义(P>0.05)。观察组患者治疗后内皮素-1(ET-1)、D-二聚体(D-D)、纤溶酶原激活物(t-PA)、纤溶酶原激活剂抑制物(PAI-1)低于对照组,踝肱指数(ABI)、趾肱指数(TBI)水平高于对照组(P<0.05);观察组患者颈股脉搏波速度(PWV)水平稍低于对照组,但差异无统计学意义(P>0.05)。观察组患者治疗后反应时间(R值)、凝固时间(K值)、血栓最大幅度(MA值)高于对照组(P<0.01)。观察组患者总不良反应发生率低于对照组(P<0.05)。结论对NVAF采用达比加群酯抗凝治疗,有利于改善血管功能,降低并发症发生率,对肝功能影响较小,安全性高。
Objective To analyze the effect of anticoagulation with dabigatran etexilate on vascular function in patients with nonvalvular atrial fibrillation(NVAF).Methods The clinical data of 120 NVAF patients from June 2013 to June 2018 were analyzed retrospectively.According to the different treatment methods,they were divided into control group(rivaroxaban treatment) and observation group(dabigatran etexilate treatment).The clinical efficacy after treatment was observed and compared between two groups.Results After 12 weeks of treatment,the total effective rate in observation group was significantly higher than that in control group(93.33% vs 76.67%,P<0.05).There was no significant difference in liver function between the two groups before and after treatment(P>0.05).Compared with control group,the levels of endothelin-1(ET-1),D-dimer,plasminogen activator(t-PA)and plasminogen activator inhibitor(PAI-1),decreased,while ankle brachial index(ABI),toe brachial index(TBI) increased in observation group(all P<0.05).The reaction time(R value),coagulation time(K value) and maximum amplitude of thrombus(MA value) in observation group were significantly higher than those in control group(all P<0.05),and the incidence of total adverse reactions was lower than that in control group(P<0.05).Conclusion For NVAF patients,anticoagulation therapy of dabigatran etexilate can improve the vascular function and reduce the incidence of complications with little effect on liver function and high safety.
作者
孙雪林
姜毅
王春艳
张运
SUN Xue-lin;JIANG Yi;WANG Chun-yan;ZHANG Yun(Department of Cardiology,l^ongkou People's Hospital,Yantai,Shandong 265701,China;不详)
出处
《中国临床研究》
CAS
2020年第3期320-323,共4页
Chinese Journal of Clinical Research
基金
烟台市科技计划项目(2016WS063)。
关键词
达比加群酯
非瓣膜性心房颤动
血管功能
安全性
Dabigatran etexilate
Nonvalvular atrial fibrillation
Vascular function
Safety
